Select Publications
Journal articles
2019, 'Medical oncologists’ experience with returning molecular tumor profiling to patients.', Journal of Clinical Oncology, 37, pp. 10521 - 10521, http://dx.doi.org/10.1200/jco.2019.37.15_suppl.10521
,2019, 'Identification of novel sarcoma risk genes using a two-stage genome wide DNA sequencing strategy in cancer cluster families and population case and control cohorts', BMC Medical Genetics, 20, http://dx.doi.org/10.1186/s12881-019-0808-9
,2019, 'FISH analysis of selected soft tissue tumors: Diagnostic experience in a tertiary center', Asia-Pacific Journal of Clinical Oncology, 15, pp. 38 - 47, http://dx.doi.org/10.1111/ajco.12980
,2019, 'The Medical Genome Reference Bank: a whole-genome data resource of 4000 healthy elderly individuals. Rationale and cohort design', European Journal of Human Genetics, 27, pp. 308 - 316, http://dx.doi.org/10.1038/s41431-018-0279-z
,2019, 'Genomic stratification and liquid biopsy in a rare adrenocortical carcinoma (ACC) case, with dual lung metastases', Cold Spring Harbor Molecular Case Studies, 5, pp. a003764, http://dx.doi.org/10.1101/mcs.a003764
,2019, 'mity: A highly sensitive mitochondrial variant analysis pipeline for whole genome sequencing data', , http://dx.doi.org/10.1101/852210
,2019, 'An Australian multi-centre experience of the use of peptide receptor radionuclide therapy for bronchial carcinoid tumours', Annals of Oncology, 30, pp. v572 - v572, http://dx.doi.org/10.1093/annonc/mdz256.021
,2018, 'The Medical Genome Reference Bank: Whole genomes and phenotype of 2,570 healthy elderly', bioRxiv, pp. 473348, http://dx.doi.org/10.1101/473348
,2018, 'Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood', Cancer Chemotherapy and Pharmacology, 82, pp. 887 - 898, http://dx.doi.org/10.1007/s00280-018-3683-8
,2018, 'Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms', Medical Decision Making, 38, pp. 954 - 967, http://dx.doi.org/10.1177/0272989X18797588
,2018, 'Cancer Molecular Screening and Therapeutics (MoST): A framework for multiple, parallel signal-seeking studies of targeted therapies for rare and neglected cancers', Medical Journal of Australia, 209, pp. 354.e1 - 354.e6, http://dx.doi.org/10.5694/MJA18.00227
,2018, 'Network-aware mutation clustering of cancer', BIORXIV, http://dx.doi.org/10.1101/432872
,2018, 'Trials and tribulations: improving outcomes for adolescents and young adults with rare and low survival cancers', Medical Journal of Australia, 209, pp. 330 - 332.e1, http://dx.doi.org/10.5694/MJA17.00976
,2018, 'Development and Pilot Testing of a Decision Aid for Genomic Research Participants Notified of Clinically Actionable Research Findings for Cancer Risk', Journal of Genetic Counseling, 27, pp. 1055 - 1066, http://dx.doi.org/10.1007/s10897-018-0223-y
,2018, 'Optical mapping reveals a higher level of genomic architecture of chained fusions in cancer', Genome Research, 28, pp. 726 - 738, http://dx.doi.org/10.1101/gr.227975.117
,2018, 'The PiGeOn project: Protocol of a longitudinal study examining psychosocial and ethical issues and outcomes in germline genomic sequencing for cancer', BMC Cancer, 18, pp. 389, http://dx.doi.org/10.1186/s12885-018-4366-x
,2018, 'Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients', International Journal of Cancer, 142, pp. 1594 - 1601, http://dx.doi.org/10.1002/ijc.31195
,2018, 'Locally aggressive connective tissue tumors', Journal of Clinical Oncology, 36, pp. 202 - 209, http://dx.doi.org/10.1200/JCO.2017.75.8482
,2018, 'A comparison of Australian and French families affected by sarcoma: Perceptions of genetics and incidental findings', Personalized Medicine, 15, pp. 13 - 24, http://dx.doi.org/10.2217/pme-2017-0035
,2018, 'Using body mapping as part of the risk assessment process - a case study', POLICY AND PRACTICE IN HEALTH AND SAFETY, 16, pp. 224 - 240, http://dx.doi.org/10.1080/14773996.2018.1491146
,2018, 'A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)', Annals of Oncology, 29, pp. viii580 - viii580, http://dx.doi.org/10.1093/annonc/mdy299.010
,2018, 'A phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)', Annals of Oncology, 29, pp. viii580 - viii581, http://dx.doi.org/10.1093/annonc/mdy299.011
,2017, 'Baseline surveillance in li-fraumeni syndrome using whole-body magnetic resonance imaging ameta-analysis', JAMA Oncology, 3, pp. 1634 - 1639, http://dx.doi.org/10.1001/jamaoncol.2017.1968
,2017, 'Is Li–Fraumeni syndrome really much more common?', Human Mutation, 38, pp. 1619, http://dx.doi.org/10.1002/humu.23342
,2017, 'Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging', JAMA oncology, 3, pp. 1735 - 1736, http://dx.doi.org/10.1001/jamaoncol.2017.1355
,2017, 'Phosphoproteomic profiling reveals ALK and MET as novel actionable targets across synovial sarcoma subtypes', Cancer Research, 77, pp. 4279 - 4292, http://dx.doi.org/10.1158/0008-5472.CAN-16-2550
,2017, 'Sociodemographic, psychosocial and clinical factors associated with uptake of genetic counselling for hereditary cancer: a systematic review', Clinical Genetics, 92, pp. 121 - 133, http://dx.doi.org/10.1111/cge.12868
,2017, 'Psychosocial morbidity in TP53 mutation carriers: is whole-body cancer screening beneficial?', Familial Cancer, 16, pp. 423 - 432, http://dx.doi.org/10.1007/s10689-016-9964-7
,2017, 'Effects of diagnosis by newborn screening for cystic fibrosis on weight and length in the first year of life', JAMA Pediatrics, 171, pp. 546 - 554, http://dx.doi.org/10.1001/jamapediatrics.2017.0206
,2017, 'Estimating TP53 mutation carrier probability in families with li-fraumeni syndrome using LFSPRO', Cancer Epidemiology Biomarkers and Prevention, 26, pp. 837 - 844, http://dx.doi.org/10.1158/1055-9965.EPI-16-0695
,2017, 'Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L', Quality of Life Research, 26, pp. 1163 - 1176, http://dx.doi.org/10.1007/s11136-016-1443-y
,2017, 'Cost-effectiveness of precision medicine in the fourth-line treatment of metastatic lung adenocarcinoma: An early decision analytic model of multiplex targeted sequencing', Lung Cancer, 107, pp. 22 - 35, http://dx.doi.org/10.1016/j.lungcan.2016.05.024
,2017, 'Myoepithelial Carcinoma of the Paracecal Mesentery: Aggressive Behavior of a Rare Neoplasm at an Unusual Anatomic Site.', Rare Tumors, 9, pp. 6504, http://dx.doi.org/10.4081/rt.2017.6504
,2017, 'IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting', Nature Communications, 8, http://dx.doi.org/10.1038/ncomms14607
,2016, 'Atypical Ewing sarcoma breakpoint region 1 fluorescence in-situ hybridization signal patterns in bone and soft tissue tumours: diagnostic experience with 135 cases', Histopathology, 69, pp. 1000 - 1011, http://dx.doi.org/10.1111/his.13031
,2016, 'Outcomes of patients with non-melanoma solid tumours receiving self-funded pembrolizumab at Chris O'Brien Lifehouse', Internal Medicine Journal, 46, pp. 1392 - 1398, http://dx.doi.org/10.1111/imj.13232
,2016, 'Sarcoma and germ-line DICER1 mutations – Authors’ reply', The Lancet Oncology, 17, pp. e471, http://dx.doi.org/10.1016/S1470-2045(16)30527-7
,2016, 'Monogenic and polygenic determinants of sarcoma risk: an international genetic study', The Lancet Oncology, 17, pp. 1261 - 1271, http://dx.doi.org/10.1016/S1470-2045(16)30147-4
,2016, 'The ENCCA-WP7/EuroSarc/EEC/PROVABES/EURAMOS 3rd European Bone Sarcoma Networking Meeting/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report', CLINICAL SARCOMA RESEARCH, 6, http://dx.doi.org/10.1186/s13569-016-0043-5
,2016, 'Realising the Value of Linked Data to Health Economic Analyses of Cancer Care: A Case Study of Cancer 2015', PharmacoEconomics, 34, pp. 139 - 154, http://dx.doi.org/10.1007/s40273-015-0343-2
,2016, 'Clinical overview of MDM2/X-targeted therapies', Frontiers in Oncology, 6, http://dx.doi.org/10.3389/fonc.2016.00007
,2016, 'Diagnosis and management of hereditary sarcoma', Recent Results in Cancer Research, 205, pp. 169 - 189, http://dx.doi.org/10.1007/978-3-319-29998-3_10
,2016, 'Mouse Models of Tumor Immunotherapy', Tumor immunology, 130, pp. 1 - 24, http://dx.doi.org/10.1016/bs.ai.2015.12.004
,2016, 'Timing and context: important considerations in the return of genetic results to research participants', Journal of Community Genetics, 7, pp. 11 - 20, http://dx.doi.org/10.1007/s12687-015-0231-7
,2016, 'Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone', Clinical Sarcoma Research, 6, pp. 15, http://dx.doi.org/10.1186/s13569-016-0056-0
,2016, 'International survey of awareness of genetic risk in the clinical sarcoma community', Asia Pac J Clin Oncol, 12, pp. 133 - 142, http://dx.doi.org/10.1111/ajco.12457
,2015, 'Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types', Journal of the National Cancer Institute, 107, http://dx.doi.org/10.1093/jnci/djv279
,2015, 'Cancer 2015: A longitudinal whole-of-system study of genomic cancer medicine', Drug Discovery Today, 20, pp. 1429 - 1432, http://dx.doi.org/10.1016/j.drudis.2015.10.009
,2015, 'Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes', British Journal of Clinical Pharmacology, 80, pp. 929 - 931, http://dx.doi.org/10.1111/bcp.12690
,2015, '“Cancer 2015”: A prospective, population-based cancer cohort—phase 1: Feasibility of genomics-guided precision medicine in the clinic', Journal of Personalized Medicine, 5, pp. 354 - 369, http://dx.doi.org/10.3390/jpm5040354
,